Education: The role of the first siderophore cephalosporin Fetcroja(®) (cefiderocol) in UK clinical practice: introduction

Welcome to this special JAC-Antimicrobial Resistance Supplement, which is sponsored by Shionogi BV. The march of increasing Gram-negative resistance is relentless, and in the last 10 years we have seen a development in the pipeline of antimicrobials targeting the most resistant Gram-negative bacteri...

Descripción completa

Detalles Bibliográficos
Autor principal: Hussain, Abid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Supplement Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251259/
https://www.ncbi.nlm.nih.gov/pubmed/34223148
http://dx.doi.org/10.1093/jacamr/dlab051
Descripción
Sumario:Welcome to this special JAC-Antimicrobial Resistance Supplement, which is sponsored by Shionogi BV. The march of increasing Gram-negative resistance is relentless, and in the last 10 years we have seen a development in the pipeline of antimicrobials targeting the most resistant Gram-negative bacteria. Within this Supplement, we will present the current landscape for Gram-negative treatments, the launch data for cefiderocol, UK potential positioning and examples of early use. The prescribing information for cefiderocol is available at: https://shionogi-eu-content.com/gb/fetcroja/pi.

Ejemplares similares